News and Updates

Together with our supporters, we have played a key role in the discovery and availability of nearly every major T1D advance and we can’t stop now. Future breakthroughs start with us. We know many of you will soon contemplate your year-end giving and will want to make the most of your charitable dollars. Fortunately, the […]

John J. McDonough was a self-made man with a successful career in business and finance. But to us, he will be remembered for his service to Breakthrough T1D and his perseverance in moving life-changing research forward for the many people living with type 1 diabetes (T1D) today. John served on our International Board of Directors […]

From August 13–22, Breakthrough T1D Game2Give held Game Over, T1D, a livestream fundraising event that raised over $60,000 for type 1 diabetes (T1D) research.

Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.

Kids with diabetes need to get back to school, but how can we best keep them safe? Experts weigh in.

Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to thrive.

Tasty, easy-to-make diabetes-friendly treats for school lunches, after school snacks, and school night dinners.

On August 2, 2021, Abbott announced the FreeStyle Libre 2 iOS app received approval from the FDA for adults and children ages 4 and up with diabetes.

The U.S. Food and Drug Administration (FDA) approved Semglee® (insulin glargine-yfgn) as the first ever interchangeable biosimilar insulin product. Semglee® (insulin glargine-yfgn) is indicated to improve glycemic control in adults and pediatric people with type 1 and adults with type 2 diabetes, and is biosimilar and interchangeable to Lantus®, a long-acting insulin. In other words, […]

Two recent publications shed light on which people with type 1 diabetes will develop end-stage kidney disease, a complication of diabetes.